Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups Thirty-eight patients ...
** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** SCCY Industries recognized a need ...
** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** SCCY has announced the new CPX Red ...
CPX-351 showed a 49% CR/CRi rate in older patients with secondary or high-risk AML, with 67% achieving MRD negativity. Early mortality was higher, and fewer patients underwent allo-HSCT compared to ...
PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 ...
PRINCETON, N.J., June 3 /PRNewswire/ -- Celator Pharmaceuticals reported positive results from its CPX-1 Phase 2 clinical trial in patients with advanced colorectal cancer. CPX-1 is a liposomal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results